Analysts Set Esperion Therapeutics Inc (ESPR) PT at $81.23

Esperion Therapeutics Inc (NASDAQ:ESPR) has been given an average rating of “Buy” by the sixteen brokerages that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $81.23.

A number of brokerages have recently commented on ESPR. Zacks Investment Research upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Chardan Capital upgraded shares of Esperion Therapeutics to a “hold” rating and set a $32.50 price target for the company in a report on Friday, July 20th. BidaskClub downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 12th. Northland Securities downgraded shares of Esperion Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, July 11th. Finally, ValuEngine upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 4th.

Esperion Therapeutics traded up $0.10, hitting $42.93, during mid-day trading on Friday, MarketBeat reports. 439,821 shares of the company’s stock traded hands, compared to its average volume of 955,596. Esperion Therapeutics has a 1 year low of $33.06 and a 1 year high of $82.68. The company has a market capitalization of $1.15 billion, a P/E ratio of -6.15 and a beta of 2.37.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.56) by ($0.17). During the same quarter in the previous year, the firm posted ($1.80) EPS. sell-side analysts predict that Esperion Therapeutics will post -6.31 EPS for the current year.

In related news, major shareholder Target N. V. Biotech bought 60,000 shares of the stock in a transaction that occurred on Thursday, June 21st. The stock was purchased at an average cost of $38.57 per share, for a total transaction of $2,314,200.00. Following the completion of the acquisition, the insider now owns 3,132,964 shares in the company, valued at $120,838,421.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Target N. V. Biotech bought 50,000 shares of the stock in a transaction that occurred on Thursday, July 12th. The stock was bought at an average price of $41.77 per share, with a total value of $2,088,500.00. Following the completion of the acquisition, the insider now owns 3,232,964 shares of the company’s stock, valued at approximately $135,040,906.28. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 460,000 shares of company stock valued at $18,278,600. 32.50% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its holdings in Esperion Therapeutics by 0.7% in the fourth quarter. Bank of New York Mellon Corp now owns 116,224 shares of the biopharmaceutical company’s stock valued at $7,652,000 after purchasing an additional 852 shares during the period. Quantbot Technologies LP grew its holdings in Esperion Therapeutics by 348.6% in the first quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 1,234 shares during the period. Swiss National Bank grew its holdings in Esperion Therapeutics by 4.7% in the first quarter. Swiss National Bank now owns 35,900 shares of the biopharmaceutical company’s stock valued at $2,597,000 after purchasing an additional 1,600 shares during the period. Stifel Financial Corp lifted its position in Esperion Therapeutics by 16.7% during the first quarter. Stifel Financial Corp now owns 12,441 shares of the biopharmaceutical company’s stock valued at $895,000 after buying an additional 1,782 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in Esperion Therapeutics by 53.9% during the first quarter. Legal & General Group Plc now owns 6,751 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 2,363 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Recommended Story: Average Daily Trade Volume – What You Need to Know

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply